Kalaris Therapeutics, Inc. Common Stock
KLRSKalaris Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company leverages its proprietary platform to discover and advance treatments aimed at modulating the immune system to restore balance and improve patient outcomes.
$9.78 +1.52 (18.40%)
Company News
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Kalaris Therapeutics secured a $50 million private placement with institutional investors to advance clinical development of TH103 for neovascular AMD, with funds expected to support operations through Q3 2027.
